Early Data On JAK Inhibitor Show Incyte And Lilly Are In The Race In Rheumatoid Arthritis
This article was originally published in The Pink Sheet Daily
Executive Summary
It's early days in the oral RA race, but data so far suggest the Incyte/Lilly compound could hold its own against Pfizer's front-runner tasocitinib.
You may also be interested in...
Positive Phase III Data For Tasocitinib Give Pfizer A Badly Needed Pipeline Lift
Pfizer retains its lead in race to bring a novel oral RA drug to market
With Lilly JAK Tie-up, Incyte Aims To Chase Pfizer In Rheumatoid Arthritis
No time to lose: A deal for an earlier-stage oral drug underscores Big Pharma's passion for new targets in inflammatory diseases.
Two-Compound Partnership With Novartis Brings Incyte $210 Million Immediately
The two companies will co-develop an oral JAK1/JAK2 inhibitor in myelofibrosis and likely other indications as well.